Core Insights - The article discusses the strategic decision by the company to voluntarily dissolve its non-wholly owned subsidiary, Shanghai Maiji Biopharmaceutical Technology Co., Ltd., to focus on core product lines amid increasing competition and resource constraints [5] - The company is advancing its key product PB-119, a long-acting GLP-1 receptor agonist, which has received acceptance for its new drug application for the treatment of type 2 diabetes by the National Medical Products Administration in September 2023 [7] - The company has also signed a collaboration agreement with PDC FZ-LLC for the exclusive development and commercialization of PB-119 in the Middle East and Africa [9] Company Strategy - The dissolution of Shanghai Maiji is seen as a proactive adjustment to concentrate resources on core projects, particularly in the metabolic and weight loss treatment sectors [5] - The company aims to enhance its product matrix centered around PB-119, which is positioned as a first-line treatment for type 2 diabetes and obesity [7] Product Development - PB-119 is designed to be administered once weekly, simplifying the clinical administration process and potentially improving patient compliance [7] - The company is also developing PB-718, a long-acting GLP-1/GCG dual receptor agonist targeting obesity and NASH, with plans for clinical trials in China [9][10]

Core Viewpoint - The company has voluntarily applied for the dissolution of its non-wholly owned subsidiary, Shanghai Maiji Biotechnology Co., Ltd., to focus on its core business and streamline operations [1] Company Summary - Shanghai Maiji was established on June 26, 2017, in China and engaged in the research and development of GLP-2, a peptide hormone involved in gut function and metabolism [1] - The decision for dissolution was made based on a shareholder resolution dated October 11, 2025, and is in accordance with Chinese law [1] - The board believes that the dissolution will not adversely affect the overall business operations and financial condition of the company or the group [1] Management Information - Michael Min Xu, the company's chairman, executive director, and general manager, is also an executive director of Shanghai Maiji, and the announcement serves to provide updated information about him as per the Hong Kong Stock Exchange Listing Rules [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 由於本公司董事長、執行董事兼總經理Michael Min XU博士（「徐博士」）為上海邁 跡的執行董事，故作出本公告亦旨在根據《香港聯合交易所有限公司證券上市規 則》第13.51(2)(l)條及13.51B(2)條的規定提供徐博士的最新資料。 除上文所披露者外，並無有關上述事宜的其他資料須敦請本公司股東垂注。 承董事會命 派格生物醫藥（杭州）股份有限公司 Michael Min XU 董事長、執行董事兼總經理 香港，2025年11月3日 於本公告日期，本公司董事會包括：(i)執行董事Michael Min XU博士及王小軍女 士；(ii)非執行董事Xiangjun ZHOU博士、徐宇虹博士、翟婷女士及李宏凱先生； 以及(iii)獨立非執行董事Jiancun ZHANG博士、陳秧秧博士及范新鵬女士。 （於中華人民共和國註冊成立的股份有限公司 ...

Core Viewpoint - The stock of Pagoda Biopharma-B (02565) surged over 20% following the announcement of a strategic partnership with UAE-based PDC FZ-LLC for the development and commercialization of its core product, Visepegenatide (PB-119), in the Middle East and Africa [1] Company Summary - Pagoda Biopharma's stock reached a new high of 62.25 HKD, with a current trading price of 60.3 HKD and a trading volume of 30.23 million HKD [1] - The strategic partnership with PDC FZ-LLC marks a significant step in Pagoda Biopharma's global commercialization strategy [1] Product Summary - Visepegenatide (PB-119) is a GLP-1 receptor agonist developed by Pagoda Biopharma, designed for weekly subcutaneous injection to treat type 2 diabetes and assist in weight management [1] - The prevalence of diabetes in the Middle East and North Africa is notably high, with a rate of 16.2% among adults, the highest globally, indicating a substantial market opportunity for Visepegenatide [1]

Core Viewpoint - The stock of Peijia Medical (02565) surged over 20% to a new high of HKD 62.25 following the announcement of a strategic partnership with UAE-based PDC FZ-LLC for the commercialization of its core product Visepegenatide (PB-119) in the Middle East and Africa [1] Company Summary - Peijia Medical's stock rose by 16.51% to HKD 60.3 with a trading volume of HKD 30.23 million [1] - The strategic partnership with PDC FZ-LLC grants exclusive rights for the development, distribution, marketing, and commercialization of Visepegenatide (PB-119) in the Middle East and Africa [1] - This collaboration represents a significant step in Peijia Medical's global commercialization strategy [1] Product Summary - Visepegenatide (PB-119) is a self-developed GLP-1 receptor agonist administered via weekly subcutaneous injection, aimed at treating type 2 diabetes and weight management [1] - The prevalence of diabetes among adults in the Middle East and North Africa is reported at 16.2%, the highest globally, indicating a substantial market opportunity for Visepegenatide [1] - The partnership is expected to accelerate the availability of this innovative therapy to address unmet medical needs in the region [1]

Major Events - Yuan Da Zhu Gong (02163) plans to apply for bankruptcy reorganization at Changsha Intermediate People's Court [1] - Yi Li Holdings (00076) subsidiary intends to issue blockchain vouchers V76, redeemable for bulk commodities on the platform [1] - Peijia Medical-B (09996): National Medical Products Administration accepts registration application for GeminiOne® transcatheter edge-to-edge repair system [1] - Paggen Biopharmaceutical-B (02565) proposes to grant exclusive license for VISEPEGENATIDE (PB-119) in the Middle East and Africa [1] - Beijing Enterprises Environment Group (00154) bids for Hong Kong I·PARK 2 project [1] - Fangda Holdings (01521) plans to acquire Shanghai Guanhua Medical Technology Co., Ltd. for 270 million yuan to enhance global laboratory service capabilities [1] - Lianzhong (06899) focuses on female user value, driving new entertainment through content [1] - Global New Materials International (06616) increases stake in CQV to 50.75%, strengthening global business collaboration [1] - Qianxin Biotechnology-B (02509): Qianxin's industrialization base successfully passes EU QP audit [1] - China Energy Construction (03996) subsidiary signs three new energy general contracting agreements, totaling approximately 19.554 billion yuan [1] - Yongyi International (01218) plans to sell all issued shares of Zhuoyi to Gaoshan (00616) [1] - Bohai Bank (09668) plans to list high capital-occupying debt assets for sale, with an initial pricing of no less than 48.883 billion yuan [1] - Chuangsheng Holdings (02680) plans to receive a premium of about 6% for full acquisition offer, resuming trading on October 13 [1] - Kelun-Botai Biopharmaceutical (06990): Core product TROP2ADC, Lukan-Satuzi (SAC-TMT) approved by National Medical Products Administration for third indication, treating EGFR mutation non-small cell lung cancer after EGFR-TKI progression [1] Operating Performance - Zhaojin Mining (01818) reports net profit of approximately 2.117 billion yuan for the first three quarters, a year-on-year increase of 140.43% [2] - Sunny Optical Technology (02382): September mobile phone camera module shipments reach 48.524 million units, a month-on-month increase of 15.3% and a year-on-year increase of 32% [2] - Yuexiu Property (00123) reports cumulative contract sales of approximately 79.812 billion yuan for the first nine months, a year-on-year increase of about 2.8% [2] - Qiu Tai Technology (01478) reports September camera module sales of 46.654 million units, a month-on-month decrease of 7.6% but a year-on-year increase of 45.1% [2]

Core Insights - The collaboration between Paige Biopharma and PDC grants exclusive rights for the development, distribution, marketing, and commercialization of Visepegenatide (PB-119) in the Middle East and Africa [1] Market Opportunity - The Middle East and North Africa (MENA) region has a high diabetes prevalence rate of 16.2%, the highest globally, driven by dietary and lifestyle factors [2] - The pharmaceutical market for digestive and metabolic drugs, including diabetes treatments, holds a 20.4% market share in the region, with a significant growth of 22.1% in Q1 2025 [2] - The number of diabetes patients in Africa is projected to increase by nearly 142% by 2050, indicating substantial market potential for diabetes and obesity treatment drugs [2] - The global weight management drug market is expected to grow from $99.7 billion in 2020 to $112.8 billion by 2024, with a compound annual growth rate (CAGR) of 3.1%, potentially reaching $277.4 billion by 2034 [2] - The demand for weight management drugs in the MENA region is anticipated to be the highest globally, potentially reaching a scale of $10 billion by 2034 [2] Product Overview - Visepegenatide (PB-119) is a once-weekly subcutaneous GLP-1 receptor agonist developed by Paige Biopharma for the treatment of type 2 diabetes and weight management [3] - The product demonstrates superior clinical characteristics compared to some existing products, including good safety, tolerability, and significant effects on blood sugar reduction and weight loss [3] - The innovative molecular design and long-acting mechanism of Visepegenatide (PB-119) provide patients with a more convenient and stable treatment option, representing the future direction of GLP-1 therapies [3] - The partnership with PDC is expected to leverage local advantages to expedite the development, registration, and commercialization of Visepegenatide (PB-119) in the MENA region, creating long-term value for the company and hope for patients with metabolic diseases globally [3]

Core Insights - The collaboration between Paige Biopharma and PDC grants exclusive rights for the development, distribution, marketing, and commercialization of Visepegenatide (PB-119) in the Middle East and Africa [1] Market Opportunity - The Middle East and North Africa (MENA) region has a high diabetes prevalence rate of 16.2%, the highest globally, driven by dietary and lifestyle factors [2] - The therapeutic area of digestive and metabolic drugs, including diabetes treatments, holds a 20.4% market share in the MENA pharmaceutical market, with a significant growth of 22.1% in Q1 2025 [2] - The number of diabetes patients in Africa is projected to increase by nearly 142% by 2050, indicating substantial market potential for diabetes and obesity treatment drugs [2] - The global weight management drug market is expected to grow from $99.7 billion in 2020 to $112.8 billion in 2024, with a compound annual growth rate (CAGR) of 3.1%, potentially reaching $277.4 billion by 2034 [2] - The demand for weight management drugs in the MENA region is anticipated to be the highest globally, reaching a scale of $10 billion by 2034 [2] Product Overview - Visepegenatide (PB-119) is a once-weekly subcutaneous GLP-1 receptor agonist developed by Paige Biopharma for the treatment of type 2 diabetes and weight management [3] - The product demonstrates superior clinical characteristics compared to some existing products, including good safety, tolerability, and significant effects on blood sugar reduction and weight loss [3] - The innovative molecular design and long-acting mechanism of Visepegenatide (PB-119) provide patients with a more convenient and stable treatment option, representing the future direction of GLP-1 therapies [3] - The partnership with PDC is expected to leverage local advantages to expedite the development, registration, and commercialization of Visepegenatide (PB-119) in the MENA region, creating long-term value for the company and hope for patients with metabolic diseases globally [3]

Core Viewpoint - The company has entered into a non-binding term sheet with PDC in the UAE for the exclusive licensing of its product Visepegenatide (PB-119), a GLP-1 receptor agonist for type 2 diabetes and weight management, marking a significant milestone in its global commercialization strategy [1][2] Group 1 - The agreement grants PDC exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa, including local production and comprehensive technology transfer [1] - The partnership is strategically important as PDC's extensive regional expertise and infrastructure can accelerate market access and penetration, validating the company's asset output strategy [1][2] - The Middle East and Africa represent a large and growing market for diabetes and obesity treatment, highlighting the unmet medical needs and commercial potential for innovative therapies like PB-119 [1] Group 2 - PDC is a leading pharmaceutical R&D institution in the region with a strong track record in clinical trials, providing end-to-end innovative solutions for clinical studies and life sciences [2] - The collaboration with PDC reinforces the company's proprietary R&D capabilities and the clinical characteristics of Visepegenatide (PB-119), showcasing its significant market potential [2] - This partnership is a crucial step in expanding the global footprint of PB-119 and aligns with the overall interests of the company and its shareholders [2]

Core Viewpoint - The company has entered into a non-binding term sheet with PDC FZ-LLC for the exclusive licensing of its product Visepegenatide (PB-119), a GLP-1 receptor agonist for treating type 2 diabetes and weight management, in the Middle East and Africa [1][2] Group 1: Licensing Agreement - The agreement grants PDC exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa [1] - This partnership is a significant milestone in the global commercialization strategy for PB-119, covering regional development, product registration, local production with full technology transfer, and exclusive commercialization rights [1] Group 2: Strategic Importance - The collaboration is strategically important as PDC's extensive regional expertise and infrastructure can accelerate market access and penetration [1] - The partnership validates the company's asset output strategy and contributes significantly to the global positioning of PB-119 and the long-term value creation for the company [1] Group 3: Market Potential - The Middle East and Africa represent a large and continuously growing market for diabetes and obesity treatment drugs, highlighting the unmet medical needs and commercial potential for innovative therapies like PB-119 [1][2] - The high prevalence and rising trend of these diseases underscore the significant market opportunity for PB-119 in these regions [1]